Royal Bank of Canada’s Anebulo Pharmaceuticals ANEB Stock Holding History

Royal Bank of Canada’s Portfolio ANEB Stock Details ANEB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-30	Closed	–	–	7067
2025 Q4	$0	Buy	+30	New	+$68	﹤0.01%	7133
2024 Q3	–	Sell	-51	Closed	–	–	6808
2024 Q2	$0	Buy	51 +13	+34%	+$33	﹤0.01%	7001
2024 Q1	$0	Sell	38 -33	-46%	-$85	﹤0.01%	6971
2023 Q4	$0	Buy	71 +23	+48%	+$54	﹤0.01%	7074
2023 Q3	$0	Hold	48	–	–	﹤0.01%	7041
2023 Q2	$0	Buy	+48	New	+$120	﹤0.01%	7212

Royal Bank of Canada's ANEB Position: Q1 2026 in Review

Royal Bank of Canada sold out of Anebulo Pharmaceuticals (ANEB) in Q1 2026, closing a stake of 30 shares.

Royal Bank of Canada first reported a position in ANEB in Q2 2023 and held it in 6 quarters. The position peaked at $0 in Q4 2025. 0 funds tracked by Wall St. Rank hold ANEB as of Q1 2026.

Royal Bank of Canada reported no remaining Anebulo Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Royal Bank of Canada sold 30 Anebulo Pharmaceuticals shares in Q1 2026.
Royal Bank of Canada first reported a position in Anebulo Pharmaceuticals in Q2 2023 and held it in 6 quarters.
Royal Bank of Canada's Anebulo Pharmaceuticals position peaked at $0 in Q4 2025.
0 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.